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Abstract
Infection with the SARS-CoV-2 virus seems to contribute significantly to increased postoperative complications and mortality after
emergency surgical procedures. Additionally, the fear of COVID-19 contagion delays the consultation of patients, resulting in the
deterioration of their acute diseases by the time of consultation. In the specific case of urgent digestive surgery patients, both factors
significantly worsen the postoperative course and prognosis. Main working hypothesis: infection byCOVID-19 increases postoperative
30-day-mortality for anycause inpatients submitted toemergency/urgentgeneral orgastrointestinal surgery.Likewise, hospital collapse
during the first wave of the COVID-19 pandemic increased 30-day-mortality for any cause. Hence, the main objective of this study is to
estimate the cumulative incidence ofmortality at 30-days-after-surgery. Secondary objectives are: to estimate the cumulative incidence
of postoperative complications and to develop a specific postoperative risk propensity model for COVID-19-infected patients.
A multicenter, observational retrospective cohort study (COVID-CIR-study) will be carried out in consecutive patients operated on
for urgent digestive pathology. Two cohorts will be defined: the “pandemic” cohort, which will include all patients (classified as
COVID-19-positive or -negative) operated on for emergency digestive pathology during the months of March to June 2020; and the
“control” cohort, which will include all patients operated on for emergency digestive pathology during the months of March to June
2019. Information will be gathered on demographic characteristics, clinical and analytical parameters, scores on the usual prognostic
scales for quality management in a General Surgery service (POSSUM, P-POSSUM and LUCENTUM scores), prognostic factors
applicable to all patients, specific prognostic factors for patients infected with SARS-CoV-2, postoperative morbidity andmortality (at
30 and 90 postoperative days). The main objective is to estimate the cumulative incidence of mortality at 30days after surgery. As
secondary objectives, to estimate the cumulative incidence of postoperative complications and to develop a specific postoperative
risk propensity model for SARS-CoV-2 infected patients.
The protocol (version1.0, April 20th 2020) was approved by the local Institutional Review Board (Ethic-and-Clinical-Investigation-
Committee, code PR 169/20, date 05/05/20). The study findings will be submitted to peer-reviewed journals and presented at
relevant national and international scientific meetings.
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Strengths and limitations of this study
 The multicentric design of the study will allow the
recording of a large number of operated patients.
 The specific emergency digestive pathology considered
and the recording of clinical conditions and prognostic
scores will reduce the heterogeneity of population
included in this study.
 The impact of SARS-CoV-2 viral status, COVID-19-
related prognostic factors, the validity of surgical
prognostic scores and the specific characteristics of initial
pandemic period in Spain (March–June 2020) on
postoperative outcomes will be assessed.
 The control cohort (same period, 2019) will represent a
proper comparative group.
 Due to the retrospective design of the study, and the very
first contact of SpanishHealth Systemwith the COVID-19
at the beginning of the study period, some datamay be lost.
1. Introduction
Since early 2020, the rapid spread of the pandemic due to the
SARS-CoV-2 virus (coronavirus 2 of severe acute respiratory
syndrome) has triggered a complex and profound global sanitary,
social, and economic crisis.[1–4] As of August 7th, 2020, the
pandemic has infected more than 18.9 million people, with a
devastating death toll of more than 709,500 worldwide (official
data from the World Health Organization, WHO).[2,5] Spain,
with more than 314,300 confirmed cases and more than 28,500
deaths, constitutes one of most severely hit countries (official data
as of 08/07/20 from the Ministry of Health, Consumption and
Social Welfare, Spain).[6,7] Multiple clinical guidelines, protocols
and recommendations have been developed to standardize
medical practice and protect both patients and professio-
nals.[8–11] All health specialties have adopted forceful contingen-
cy plans and a profound reorganization of their healthcare
activity.[7,11] Emergency digestive surgery has not been differ-
ent.[11–15] During the period of maximum impact of the
pandemic, most scheduled surgical interventions were drastically
reduced or suspended, operating rooms were converted into
critical care units, and highly versatile surgical staff were
redistributed to medical services.[14,16–20] However, urgent and
“non-delayable” interventions continued to be performed in
patients whowere occasionally infectedwith SARS-CoV-2.[13,20–23]
Some publications suggest that surgical procedures accelerate
and exacerbate the clinical progression of COVID-19.[17,24]
Several teams have recently described classic emergency surgical
pathologies with “atypical” forms of presentation and/or
complicated postoperative evolution, differing from the usual
“pre-pandemic” scenario.[10,13,25–28]
Urgent and emergency digestive interventions, extremely
prevalent in our setting, are always associated with a high risk
of complications and mortality, compared to elective surger-
ies.[29,30] In the current context of the COVID-19 pandemic, in
addition to the preoperative risk factors and the peculiarities
inherent in all emergency surgery, other different elements seem
to influence the worst postoperative prognosis, even in COVID-
19-negative patients.[21,31] Several factors may be involved:
1. patients’ fear of visiting the hospital during the pandemic (and/
or home confinement) makes that clinicians face with more
advanced surgical pathologies in the moment of consultation;
2. “saturation” of the health system, collapse of the emergency
departments, and the misinterpretation of septic symptoms in
this context can easily add an “extra” delay in diagnosis;
3. conservative treatment (nonsurgical management) may be
forced beyond usual local standards, making patients who
ultimately need a surgical rescue worse off;
4. work overload of supporting services, such as intensive care
units and interventional radiology, may increase “failure to
rescue” in complicated patients, not just COVID-19-positive
patients.[16,21–23,32–35]
Furthermore, we can’t exclude a synergistic negative effect of
SARS-CoV-2 infection on the acute disease that prompted
surgical consultation.[35]
The COVID-19 pandemic seems to directly or indirectly
modify the clinical profile of the urgent surgical pathology treated
in a General Surgery Emergency Department (epidemiology,
surgical indications, clinical severity, diagnostic delay, compli-
cations, etc.).[21,36] The surgical indications and operative
techniques for urgent digestive surgeries performed during
the “pandemic” period may differ from the “pre-pandemic”
period, as well as the postoperative complication and mortality
rates of COVID-19-negative patients during the pandemic
period.[21,23,25,37]
Digestive surgeons ask several questions in this particular
epidemiological context:
1. To what extent does COVID-19 infection modify the nature,
clinical profile, or postoperative evolution of urgent surgical
pathology?;[17,21,26]
2. Does the socio-sanitary context of a pandemic modify the
presentation, severity, diagnostic delay, or postoperative
evolution of COVID-19-negative patients undergoing emer-
gency surgery?;[21,32]
3. Do the usual postoperative risk prediction scales maintain
their validity in this period or do they require any kind of
adjustment based on other specific prognostic criteria?;[38,39]
4. Is it appropriate to perform emergency surgical interventions
with the classic clinical indications or should some acute
pathologies be deferred and the surgery be postponed until
normal conditions prevail?;[10,15,25,36,37]
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5. Are all the surgical techniques and approaches commonly used
in emergency digestive surgery equally safe during COVID-19
pandemic period?[9,23,33,36,37,40]
These and other questions should be answered as soon as
possible. The analysis of real data on urgent gastrointestinal
surgery in patients operated on during this period could provide
the necessary information.[36,41] However, in order to control the
confounding factors of the pandemic scenario, cohort studies
should provide additional information on the pathology and
clinical condition of patients at the time of urgent surgery, for
example with prognostic surgical scores. The classic surgical
prognostic scales validated for the estimation of postoperative
risk (scores POSSUM-mortality, POSSUM-morbidity, P-POS-
SUM, LUCENTUM-logistic regression, and LUCENTUM-
CHAID) may not be adequate in patients undergoing emergency
surgery during the pandemic period.[38,39,42–45] Therefore, it may
be necessary to consider other prognostic factors and design a
new and specific prediction model for patients infected with
SARS-CoV-2.[46,47] Currently, we only have extrapolated
prognostic scores for the set of COVID-19-positive patients,
with little data on the specific subgroup of surgical patients, and
even less information on the postoperative evolution after urgent
digestive surgery.[15,21,22,48–51]
It would also be advisable to compare a COVID-19-positive
group of patients with a simultaneous COVID-19-negative group
(both in the “pandemic period”) and with a “pre-pandemic”
control group in the same hospitals.
A registry of these characteristics would provide firmer evidence
on their clinical profile and would make it possible to adequately
estimatepatient’spostoperative risk.[46]The fewstudies published to
date address these issues superficially, with unadjusted rawdata and
a low degree of statistical analysis and scientific evidence.[10,35,52]
To contribute to the clarification of these doubts, we propose a
multicenter, observational study (“COVID-CIR” study), in
which multiple digestive surgical teams from different areas of
Spain severely affected by the COVID-19 pandemic will
participate. Main working hypothesis: infection by COVID-19
increases postoperative 30-daymortality for any cause in patients
submitted to emergency/urgent general or gastrointestinal
surgery. Likewise, hospital collapse during the first wave of
the COVID-19 pandemic increased 30-day mortality for any
cause in COVID-19-non-infected patients who required emer-
gency/urgent general or gastrointestinal surgery. Hence, the main
objective of this study is to estimate the cumulative incidence of
mortality at 30days after surgery. Secondary objectives are: to
estimate the cumulative incidence of postoperative complications
and to develop a specific postoperative risk propensity model for
COVID-19 infected patients.
The conclusions of this study could contribute to design a
future action plan for similar epidemiological situations or
subsequent outbreaks of SARS-CoV-2.[20,41,53]
2. Methods and analysis
This protocol is reported in accordance with the STROBE
guideline.[54]
2.1. Study design
COVID-CIR is an observational, multicenter, cohort study of
patients undergoing emergency/urgent gastrointestinal surgery
during the period of maximum impact of the COVID-19
pandemic in Spain (from March 1st to June 30th, 2020).[6,13]
This study was registered in the ClinicalTrials.gov Protocol
Registration and Results System (Identifier: NCT04479150, July
21st, 2020).
2.1.1. Ethical issues. The study conforms to the stipulations of
the Declaration of Helsinki. The protocol was approved by the
local Institutional Review Board (Ethics and Clinical Investiga-
tion Committee of the Hospital Universitari de Bellvitge, code
PR169/20, date approval 05/05/20) and a waiver for written
informed consent was given, as no additional procedures or
information will be required from participants beyond that which
would normally take place as part of clinical care. The list of local
Institutional Review Board members is available at https://
bellvitgehospital.cat/es/investiga-con-nosotros/ceic/composicion
(accessed on August 11th, 2020). The level of protection of
confidentiality, in terms of protection of personal data as required
by Spanish Law (Organic Law onData Protection 3/2018), is also
ensured. The study findings will be submitted to peer-reviewed
journals and presented at relevant national and international
scientific meetings.
2.2. Settings
A total of 30 surgical teams from different Spanish hospitals have
been proposed to participate in this study (see Supplementary
data file 1, http://links.lww.com/MD/F600), which has been
coordinated by the Department of General and Digestive Surgery
of the Bellvitge University Hospital (L’Hospitalet de Llobregat,
Barcelona, Spain). All hospitals participating are from Spain,
with different surgical capabilities.[55]
2.3. Study population
Patients operated on for emergency/urgent gastrointestinal
surgery constitute the target population. Table 1 shows the list
of all the urgent gastrointestinal surgery procedures under study.
There is no patient or public involvement in the design, conduct,
reporting, or dissemination plans of the study.
 Inclusion criteria: ≥18years, both genders, and operated on for
urgent/emergency gastrointestinal pathology.
 Exclusion criteria: patients who have undergone a scheduled
surgical intervention or patients operated on by a service other
than General and Digestive Surgery.
Two cohorts will be defined:
1. Cohort A: consecutive patients who required emergency/
urgent gastrointestinal surgery from March 1st to June 30th,
2020 (“first wave” of the COVID-19 pandemic in Spain). This
cohort will be stratified by SARS-CoV-2 infection status
(according to the RT-PCR [Reverse Transcription-Polymerase
Chain Reaction] test, or serological detection of antibod-
ies):[8,11,14,17,46]
 COVID-19-positive patients (infected by SARS-CoV-2), and
 COVID-19-negative patients (not infected by SARS-CoV-2).
2. Cohort B: consecutive patients who required emergency/
urgent gastrointestinal surgery from March 1st to June 30th,
2019 (control cohort of a “pre-pandemic” period).
Figure 1 shows the flow diagram of the study. Table 2
shows the complete list of postoperative complications and
Table 3 shows the Clavien-Dindo classification for complica-
tions.[56,57]
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2.4. Study timeline
The study period has been delimited by the period of the
“COVID-19 pandemic”: March 1st to June 30th, 2020. In Spain,
this period corresponds to the maximum impact of the pandemic
on health services (due to contingency plans and the reorganiza-
tion of medical services) and society at large (due the “state
of alarm” implemented by the Spanish government, which
resulted in home confinement, restrictions on mobility and other
preventive measures).[6]
Schedule the study protocol was drawn up in March and April
2020. The IRB (Institutional Review Board) approved the
protocol on May 5, 2020 (code PR169/20, date 05/05/20).
At the moment of submitting this manuscript, participant
recruitment is in progress. The inclusion of patients data does not
end until August 31st, 2020. Provided the 30-day follow-up of
the last included patient is completed by July– to August 2020,
and that 1 month will be required for database cleaning and
statistical analysis, it is expected that the first results (including
30-day morbidity/mortality) will be available in September to
October 2020. Complete analysis (including 90-day mortality)
will be available in November to December 2020. Table 4 depicts
the study schedule.
2.5. Outcomes
 The primary outcome is the cumulative incidence of mortality
for any cause at 30days after urgent gastrointestinal surgery.
 Secondary outcomes are:
1. Cumulative incidence of all-causes mortality within 90days
after surgery.
2. Cumulative incidence of any postoperative morbidity within






























Figure 1. Flow diagram of the study.
Table 1
Urgent gastrointestinal surgical procedures according to the
degree of surgical complexity.
• Minor Complexity
- Hernia/eventration
- Perianal surgery, pilonidal sinus
• Moderate Complexity
- Cholecystectomy (open or laparoscopic)
- Appendectomy (open or laparoscopic)
• Major Complexity
- Gastrointestinal perforation suture
- Intestinal resection
- Colectomy
- Main bile duct surgery
- Gastrectomy
- Lysis of adhesions or reduction of internal hernia or enterolithotomy
- Splenectomy or minor liver trauma
- Exploratory laparotomy
- Surgical hemostasis due to hemoperitoneum
• Major + Complexity
- Open pancreatic necrosectomy
- Pancreatectomy
- Damage control surgery (due to trauma, bleeding, ischemia or peritonitis)
• Others
Madrazo et al. Medicine (2021) 100:5 Medicine
4
and/or complications specifically associated with the evolution
of COVID-19 (Table 2).[8,58]
3. Cumulative incidence of severe 30 day-postoperative compli-
cations, >IIIA grade according to the Clavien-Dindo score
(Table 3).[56,57,59]
4. Failure-to-rescue defined as the percentage of patients dying of
any cause as a consequence of any postoperative complication.
5. Length of hospital stay (from the day of admission to the date
of hospital discharge or death).
6. “Physiological” and “operative severity” to calculate the
estimated risks of mortality and postoperative complications
according to 5 surgical prognostic scales (Table 5): POSSUM-
mortality and POSSUM-morbidity scores, P-POSSUM score,
LUCENTUM-logistic regression, and LUCENTUM-CHAID
scores.[14,38,39,42–45]
7. Attitude of the surgeons due to the influence of the SARS-CoV-
2 pandemic regarding the “moment of surgical interven-
tion”:[21,22,32,33] Did it change? [No/Yes]; if affirmative:
Table 3
Severity of postoperative complications according to Clavien-Dindo system.
Degree Definition
I Any deviation from the normal postoperative course that does not require surgical, radiological or endoscopic intervention. Includes additional use of
electrolyte solutions, diuretics, antiemetics, antipyretics, analgesics and physiotherapy. Includes superficial infection or seroma/hematoma treated at
the bedside.
II Different pharmacological treatment than the above ones is required, including blood transfusions, antibiotics and total parenteral nutrition.
III Requires surgical, endoscopic or radiological intervention:
a No general anesthesia
b Under general anesthesia
IV Life-threatening complication requiring treatment in intermediate or intensive care unit:
a Single organ dysfunction (includes haemodialysis)
b Multiple organic dysfunction
V Patient death
Grades above IIIa (grades IIIb, IVa, IVb or V) are considered “severe complications”.
Table 2
Listing and description of postoperative complications.
• Anastomotic dehiscence/intestinal fistula: clinical or radiological data of extravasation of intestinal content through an anastomosis, drainage, surgical wound, or abnormal
hole
• Superficial wound dehiscence (full fascia)
• Evisceration (clinical or radiological; includes any degree)
• Heart failure or acute pulmonary edema: symptoms or signs of left or congestive ventricular insufficiency (change from preoperative situation)
• Fever of unknown origin: mantained fever >37°C for ≥24 hours, of unknown cause, after usual immediate postoperative temperature increase
• Mild hemorrhage: postoperative hemorrhage that does not require surgical re-examination or endoscopic/radiological procedure for treatment
• Severe bleeding: postoperative hemorrhage that does require surgical re-examination or endoscopic/radiological procedure for treatment
• Hypotension: maintained drop of systolic pressure to <90 mm Hg for >24 hours, detected with sphygmomanometer or arterial catheter
• Superficial wound infection: redness and pain around the surgical wound or local suppuration
• Deep wound infection: intra-abdominal collection (abscess), clinically or radiologically confirmed, or release of purulent content through a drainage
• Respiratory infection or pneumonia: purulent sputum with positive bacteriological/virological culture, with or without changes in chest X-ray, or fever with pulmonary
radiological consolidation
• Urinary tract infection: urinary symptoms or fever, associated with sediment with bacteriuria/leukocyturia or positive urine culture
• Renal failure: sharp increase in creatinine to ≥2 mg/dl (≥177mmol/L) in patients with normal prior renal function, or a sharp increase in creatinine (>50%) in patients with
chronic kidney failure, or need for renal replacement therapy
• Respiratory failure: breathing difficulty requiring emergency ventilatory support, or PaO2 <60 mm Hg and PaCO2 >45 mm Hg breathing ambient air
• Bacteremia-Sepsis: positive blood culture
• DVT (deep vein thrombosis) and/or PE (pulmonary embolism): clinical suspicion, radiological confirmation by ECO-doppler, chest-computed tomography or ventilation/perfusion
scan, or postmortem diagnosis
• Postoperative ileus
• Pleural effusion/pulmonary atelectasis
• Intestinal perforation
• Seroma or surgical wound hematoma
• Intestinal occlusion
• Ostomy complications (bleeding, retraction, infection, dermatitis, fistula, stoma necrosis)
• Blood glucose disturbances maintained >24 hours
• Atrial fibrillation
• Hypertensive crises (systolic blood pressure >200 mm Hg and/or diastolic blood pressure >120 mmHg)
• Acute confusion syndrome
• Gastrointestinal bleeding (upper or lower)
• Acute myocardial infarction, cerebrovascular accident or acute limb ischemia (peripheral artery ischemia)
• Acute mesenteric ischemia (intestinal ischemia, small bowel or colon)
• Cardiomyopathy or pericarditis
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-Was the patient probably seen for consultation later than
usual (more advanced pathology)?
-Was the diagnosis of the surgical pathology delayed?
-Was urgent intervention delayed for logistical problems
(“hospital” delay)?
-Was a conservative/non-operative treatment “over-
indicated”?
8. Attitude of the surgeons due to the influence of the SARS-
CoV-2 pandemic regarding the “surgical technique”
used:[9,10,15,36,37,40] Did it change? [No/Yes]; if affirmative:
-Was the surgical technique being “more conservative than
usual” or “more aggressive than usual”?
2.6. Data collection
All data will be gathered from electronic medical record. All
consecutive patients operated on for urgent digestive surgery
during the study period will be screened and included if they fulfil
the inclusion criteria.
Demographic characteristics, comorbidities, clinical and
analytical variables, SARS-CoV-2 infectious status (pre- and
post-operative periods), clinical diagnosis, intraoperative find-
ings and postoperative course (30-day morbidity, 30-day
reinterventions, hospital stay, 30-day readmissions, and mortali-
ty at 30 and 90days) will be recorded (Supplementary data file 2,
http://links.lww.com/MD/F601).[25,35]
All values necessary for the automatic calculation of the
surgical prognostic scores shall also be included (Table 5).[39,45]
Prognostic factors recently described in COVID-19-positive
patients will also be recorded: advanced age, hypertension,
smoking, diabetes, chronic obstructive pulmonary disease
(COPD), cardiovascular history, lymphocyte and platelet count,
alanine-aminotransferase (ALT), C-reactive protein (CRP), D-
dimer, ferritin, procalcitonin (PCT), lactate-dehydrogenase
(LDH), troponin, prothrombin time, “neutrophil-to-lymphocyte
ratio” (NLR) and “platelet-to-lymphocyte ratio”
(PLR).[8,11,16,26,35,49,50,60–64]
Among postoperative complications, those currently consid-
ered “characteristics” of COVID-19 (pneumonia, respiratory
failure, venous thromboembolism, acute myocardial infarction,
cerebrovascular accident, peripheral arterial ischemia, intestinal
ischemia, cardiomyopathy, or pericarditis) will be analyzed in
depth.[8,35,58]
An electronic Case Report Form (eCRF), based on REDCap
platform (Research Electronic Data Capture software, REDCap
Consortium), has been created ad hoc for this study (Supplemen-






Day of hospital discharge/death Day 30 of surgery Day 90 of surgery
Inclusion/exclusion criteria ✓
Day of surgery ✓
Demographic data† ✓
Clinical data† ✓
Prognostic scores (see Table 5) ✓
Presurgery evaluation ✓
Urgent surgery characteristics (see Table 1) ✓
Postsurgery evaluation: Mortality ✓ ✓ ✓
Postsurgery evaluation: Morbidity (see Table 2) ✓ ✓
In cohort 2020, COVID-19-positive:
• RT-PCR or serological detection ✓
In cohort 2020, COVID-19-positive:
• COVID-19-related complications‡ ✓ ✓
∗
patients operated on March, April, May, June, 2020 (cohort 2020) and 2019 (cohort 2019).
† see Supplementary data file 2, http://links.lww.com/MD/F601 (eCRF variables by category).
‡ pneumonia, respiratory failure, venous thromboembolism (deep vein thrombosis or pulmonary embolism), acute myocardial infarction, cerebrovascular accident, peripheral arterial ischemia, acute mesenteric




POSSUM (mortality) Ln [R/(1–R)] = –7.04 + (0.13  physiological score) + (0.16  operative severity score) Postoperative mortality
POSSUM (morbidity) Ln [R/(1–R)] = –5.91 + (0.16  physiological score) + (0.19  operative severity score) Postoperative morbidity
P-POSSUM Ln [R/(1–R)] = –9.065 + (0.1692  physiological score) + (0.155  operative severity score) Postoperative mortality
LUCENTUM-logistic regression Ln [R/(1–R)] = –4.461 + (0.257  age) + (0.261  sodium) + (0.167  Hb) +
(0.364  white cell count) + (0.397  operative severity)
Postoperative morbidity
LUCENTUM-CHAID Ln [R/(1–R)] = –5.835 + (0.757  cardiac function) + (0.563  sodium) +
(0.411  peritoneal soiling) + (0.778  operative severity)
Postoperative morbidity
R: predicted risk of postoperative mortality/morbidity (30days); Hb: hemoglobin (g/dl). Units for POSSUM and P-POSSUM scores: total physiological and operative severity score.[38,39,42,43] Units for LUCENTUM
scores: age (years); sodium (mmol/L); hemoglobin (g/dL); white cell count (109/L); operative severity (minor, moderate, major, major+); cardiac function (no failure, any abnormality); peritoneal soiling (none/
serous, local pus/diffuse peritonitis/hemoperitoneum/free bowel content).[44,45]
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2.7. Data quality
Before closing the database for analysis, the datamanager and the
2 principal investigators of the study (JO and ZM) will contact
the senior local surgeon from each center in order to confirm
completeness and accuracy of recorded data. Hospitals which
failed to include all eligible patients of both periods will be
excluded for analysis to avoid a selection bias. Hospitals failing to
include at least 90% of operated patients fulfilling inclusion
criteria during the study periods will be excluded for analysis in
order to avoid selection bias. Moreover, patients with relevant
missing information (age, sex, functional status, previous
comorbidities, malignancy, COVID-19 infection status, date of
surgery, urgency, type and complexity of surgery, and 30-day
postoperative follow-up) will be also excluded.
2.8. Sample size
Due to the exploratory nature of our aim, no formal calculation
of sample size was performed. It will be defined by the total
number of patients who underwent emergency gastrointestinal
surgery during the 2 study periods at the participating hospitals.
We expect to include more than 2000 patients.
2.9. Statistical analysis
Baseline characteristics will be described using standard
descriptive statistics, and a descriptive and exploratory compar-
ative analysis between both cohorts will be carried out.
The cumulative incidence of mortality (and its 95% confident
interval) and the incidence of morbidity (and its 95% confident
interval) at 30 and 90days will be estimated by positive/negative
SARS-CoV-2 infection status (cohort A) and in the control group
(cohort B).
To minimize the selection bias effect of potential confounders,
propensity scores will be estimated using a multinomial model to
estimate the probability that subjects were SARS-CoV-2-
positive, SARS-CoV-2-negative or control. Subjects will be
matched using the propensity scores. After matching, to
identify imbalance between groups, the standardized mean
difference will be estimated and plotted. In the matched sample,
the cumulative incidence of mortality (and its 95% confidence
interval) and the incidence of morbidity (and its 95% confidence
interval) at 30 and 90days will be compared using a generalized
linear model with a binomial distribution and a logarithm link
function. Those variables that remain imbalanced between
groups after matching would be added to the model with an
adjusting purpose.
A generalized linear model with a binomial distribution and a
logarithm link function will be used to estimate relative risk as a
measure to indentify prognostic factors associated with 30 and
90days mortality and morbidity incidences. Five predictive
scores of postoperative morbidity and/or mortality will be
calculated according with Table 5: POSSUM-mortality, POS-
SUM-morbidity, P-POSSUM, LUCENTUM-logistic regression,
and LUCENTUM-CHAID.[38,39,42–45] Their applicability on
postoperative morbidity or mortality prediction in COVID-19
pandemic will be assessed.
Data analysis will be carried out using R version 4.02 or
superior (R Core Team, 2019; R: A language and environment
for statistical computing. R Foundation for Statistical Comput-
ing, Vienna, Austria. URL https://www.R-project.org/).
3. Discussion
The COVID-19 worldwide pandemic, officially declared on
March 11, 2020 byWHO, has drastically transformed the global
socio-health landscape.[2–5,8,66] Spain is one of the most affected
countries by this unprecedented health crisis, ranking among the
top nations in infected population, infected health workers, and
deaths.[6,13,55,67] All medical and surgical specialties have been
closely affected.[12,13,22,68,69]
In the particular context of urgent surgery, SARS-CoV-2 virus
infection appears to contribute to a significant increase in
postoperative morbidity and mortality, higher than
expected.[22,25,27,35] Secondary “cytokine storm”, endothelial
injury and microangiopathy, and the complex interaction of the
virus with the immune system could explain (at least partially)
this significant deterioration of the postoperative course
described by several groups, especially in elderly patients and/
or with associated diseases.[8,11,26,35,58,60,61,70] Simultaneously,
during the pandemic period, acute surgical pathologies attended
in the emergency departments appear in more advanced stages
and associate worse postoperative course, even in patients not
affected by SARS-CoV-2.[21–23,32,37]
Risk scales (scores) for postoperative morbidity and/or
mortality (POSSUM, P-POSSUM, and LUCENTUM scores)
are essential for the outcomes of rigorous surgical audits, quality
care controls and as a comparative framework (intra- or inter-
hospital) of clinical outcomes.[71] There is not information about
the validity of these surgical predictive scores regarding urgent
digestive surgery in COVID-19-positive or COVID-19-negative
patients.[14,39,45] Therefore, it is necessary to establish the
predictive capacity of these scales and/or to select other
significant prognostic factors in the COVID-19 pandemic
period.[35,41,46,48]
This protocol has been designed to specifically assess the effect
of the COVID-19 pandemic on patients (infected or not by SARS-
CoV-2) operated on for some urgent digestive pathology (Table 1)
during the period of maximum social and health impact of the
disease in several hospitals in Spain.[5,16,35] At the same time, the
COVID-19-negative subgroup of patients in the 2020 cohort will
be contrasted with the 2019 control group (“pre-pandemic”), in
order to compare mortality rates and detect differences in clinical
indications, surgical techniques used, and postoperative evolu-
tion between the 2 epidemiological contexts.[15,33,36,37] The
analysis of the data could provide us with useful information on
the main predictors of postoperative complications or mortality
of COVID-19-positive patients.[41]
Through an online electronic Case Report Form (eCRF) on
REDCap platform,[65] researchers from multiple Spanish hospi-
tals will record the variables necessary to subsequently develop a
comparison of the characteristics, postoperative morbidity, and
mortality rates[25,72] in 2 cohorts of patients operated on
emergency digestive pathology: patients COVID-19-positive
and COVID-19-negative operated during March to June 2020,
and a control cohort of patients operated during the same period
of the previous year (March–June 2019).[23,25]
As a secondary objective of the study, we are confident of
obtaining sufficient data to develop our own model of
postoperative risk prediction, specific to patients infected with
SARS-CoV-2 (COVID-19-positive), as a useful short-, medium,
and long-term clinical tool for clinical decision-making.[52]
This study has some limitation, including its inherent
observational nature and the potential loss of perioperative
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analytical data (particularly, analytical parameters related to
COVID-19 infection: CRP, D-dimer, ferritin, procalcitonin,
LDH, and troponin), especially during the “pre-pandemic”
period and the first weeks of the “pandemic period” (the
beginning of health contact with the SARS-CoV-2 virus in Spain
and/or absence of specific COVID-19 protocols or analytical
profiles).
The information provided by this study could be a useful and
extrapolable tool to surgical teams for urgent surgical decision-
making on indications, surgical techniques, and resource
management, both in the current pandemic context and in
anticipation of future SARS-CoV-2 outbreaks.[20,22,25,41,53]
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